3 Stocks Moving The Drugs Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 10 points (-0.1%) at 17,605 as of Wednesday, Nov. 12, 2014, 12:20 PM ET. The NYSE advances/declines ratio sits at 1,473 issues advancing vs. 1,490 declining with 167 unchanged.

The Drugs industry currently sits down 0.1% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Intercept Pharmaceuticals ( ICPT), down 6.8%, Sanofi ( SNY), down 1.7%, Grifols ( GRFS), down 1.4% and Vertex Pharmaceuticals ( VRTX), down 1.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Regeneron Pharmaceuticals is up $2.03 (0.5%) to $400.39 on light volume. Thus far, 268,095 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 796,200 shares. The stock has ranged in price between $395.81-$401.40 after having opened the day at $396.20 as compared to the previous trading day's close of $398.36.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $38.5 billion and is part of the health care sector. Shares are up 44.7% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Allergan ( AGN) is up $1.15 (0.6%) to $196.49 on heavy volume. Thus far, 2.7 million shares of Allergan exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $192.12-$200.60 after having opened the day at $192.12 as compared to the previous trading day's close of $195.34.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $58.2 billion and is part of the health care sector. Shares are up 75.9% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Allergan a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Allergan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is up $0.20 (0.7%) to $30.52 on light volume. Thus far, 8.7 million shares of Pfizer exchanged hands as compared to its average daily volume of 24.4 million shares. The stock has ranged in price between $30.23-$30.54 after having opened the day at $30.23 as compared to the previous trading day's close of $30.32.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. Pfizer has a market cap of $190.3 billion and is part of the health care sector. Shares are down 1.0% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%